These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7380205)

  • 41. Medroxyprogesterone acetate does not induce antipyrine clearance and only weakly increases alpha 1-acid glycoprotein in beagle dogs.
    Abramson FP; Moore CF; Hill MD
    Res Commun Chem Pathol Pharmacol; 1986 Jul; 53(1):65-78. PubMed ID: 2944196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver function and medroxyprogesterone acetate elimination in man.
    Rautio A
    Biomed Pharmacother; 1984; 38(4):199-204. PubMed ID: 6498308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
    Lenaerts A; Codden T; Henry JP; Van Cauter J; Meunier JC; Ligny G
    Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spironolactone-induced hyperchloremic acidosis in cirrhosis.
    Gabow PA; Moore S; Schrier RW
    Ann Intern Med; 1979 Mar; 90(3):338-40. PubMed ID: 426401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal.
    Henriksen JH; Holst JJ; Møller S; Brinch K; Bendtsen F
    Hepatology; 1999 Jun; 29(6):1818-24. PubMed ID: 10347125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver size in evaluating drug metabolizing capacity in man.
    Pirttiaho H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
    Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of fenfluramine on disposition and rate of antipyrine elimination.
    O'Malley K; Stevenson IH; West M
    Pharmacology; 1975; 13(1):12-9. PubMed ID: 1153500
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The impact of carnitine on serum ammonia concentration and lipid metabolism in patients with alcoholic liver cirrhosis].
    Łapiński TW; Grzeszczuk A
    Pol Merkur Lekarski; 2003 Jul; 15(85):38-41. PubMed ID: 14593957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism.
    Campillo B; Sherman E; Richardet JP; Bories PN
    Eur J Clin Nutr; 2001 Nov; 55(11):980-8. PubMed ID: 11641747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea.
    Decaux G; Mols P; Cauchie P; Flamion B; Delwiche F
    Nephron; 1986; 44(4):337-43. PubMed ID: 3796773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis.
    Larrey D; Lebrec D; Bercoff E; Pessayre D
    Clin Sci (Lond); 1983 Aug; 65(2):203-5. PubMed ID: 6602683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.
    Lenaerts A; Codden T; Meunier JC; Henry JP; Ligny G
    Hepatology; 2006 Oct; 44(4):844-9. PubMed ID: 17006921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of the total hepatic function after treatment with fosinopril in hypertensive patients with liver cirrhosis].
    Loguercio C; Piscopo P; Guerriero C; Valese C; De Girolamo V
    Clin Ter; 1994 Dec; 145(12):475-9. PubMed ID: 7720355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
    Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
    Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.
    Le Couteur DG; Hickey H; Harvey PJ; Gready J; McLean AJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1553-8. PubMed ID: 10336552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].
    Cho HS; Park GT; Kim YH; Shim SG; Kim JB; Lee OY; Choi HS; Hahm JS; Lee MH
    Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):324-31. PubMed ID: 14695699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alterations in the disposition of differently cleared drugs in patients with cirrhosis.
    Klotz U; Fischer C; Müller-Seydlitz P; Schulz J; Müller WA
    Clin Pharmacol Ther; 1979 Aug; 26(2):221-7. PubMed ID: 455890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.